159 related articles for article (PubMed ID: 27251038)
1. A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.
Garrigou S; Perkins G; Garlan F; Normand C; Didelot A; Le Corre D; Peyvandi S; Mulot C; Niarra R; Aucouturier P; Chatellier G; Nizard P; Perez-Toralla K; Zonta E; Charpy C; Pujals A; Barau C; Bouché O; Emile JF; Pezet D; Bibeau F; Hutchison JB; Link DR; Zaanan A; Laurent-Puig P; Sobhani I; Taly V
Clin Chem; 2016 Aug; 62(8):1129-39. PubMed ID: 27251038
[TBL] [Abstract][Full Text] [Related]
2. Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases.
Chen ZG; Ji XM; Xu YX; Fong WP; Liu XY; Liang JY; Tan Q; Wen L; Cai YY; Wang DS; Li YH
Ther Adv Med Oncol; 2024; 16():17588359241230752. PubMed ID: 38425989
[TBL] [Abstract][Full Text] [Related]
3.
Raunkilde L; Hansen TF; Andersen RF; Havelund BM; Thomsen CB; Jensen LH
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139621
[TBL] [Abstract][Full Text] [Related]
4. Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy.
Hiley CT; Swanton C
Cancer Discov; 2016 Feb; 6(2):122-4. PubMed ID: 26851181
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon JJ; Simmons AD; Lovejoy AF; Esfahani MS; Newman AM; Haringsma HJ; Kurtz DM; Stehr H; Scherer F; Karlovich CA; Harding TC; Durkin KA; Otterson GA; Purcell WT; Camidge DR; Goldman JW; Sequist LV; Piotrowska Z; Wakelee HA; Neal JW; Alizadeh AA; Diehn M
Nat Commun; 2016 Jun; 7():11815. PubMed ID: 27283993
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?
Leung F; Kulasingam V; Diamandis EP; Hoon DS; Kinzler K; Pantel K; Alix-Panabières C
Clin Chem; 2016 Aug; 62(8):1054-60. PubMed ID: 27259816
[No Abstract] [Full Text] [Related]
7. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
[No Abstract] [Full Text] [Related]
8. The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer.
He WS; Bishop KS
Expert Rev Mol Diagn; 2016 Aug; 16(8):839-52. PubMed ID: 27254598
[TBL] [Abstract][Full Text] [Related]
9. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma.
Burnham P; Kim MS; Agbor-Enoh S; Luikart H; Valantine HA; Khush KK; De Vlaminck I
Sci Rep; 2016 Jun; 6():27859. PubMed ID: 27297799
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
11. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Jansen MP; Martens JW; Helmijr JC; Beaufort CM; van Marion R; Krol NM; Monkhorst K; Trapman-Jansen AM; Meijer-van Gelder ME; Weerts MJ; Ramirez-Ardila DE; Dubbink HJ; Foekens JA; Sleijfer S; Berns EM
Oncotarget; 2016 Jul; 7(28):43412-43418. PubMed ID: 27270325
[TBL] [Abstract][Full Text] [Related]
12. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
[TBL] [Abstract][Full Text] [Related]
13. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
Oddo D; Sennott EM; Barault L; Valtorta E; Arena S; Cassingena A; Filiciotto G; Marzolla G; Elez E; van Geel RM; Bartolini A; Crisafulli G; Boscaro V; Godfrey JT; Buscarino M; Cancelliere C; Linnebacher M; Corti G; Truini M; Siravegna G; Grasselli J; Gallicchio M; Bernards R; Schellens JH; Tabernero J; Engelman JA; Sartore-Bianchi A; Bardelli A; Siena S; Corcoran RB; Di Nicolantonio F
Cancer Res; 2016 Aug; 76(15):4504-15. PubMed ID: 27312529
[TBL] [Abstract][Full Text] [Related]
14. A novel strategy for highly efficient isolation and analysis of circulating tumor-specific cell-free DNA from lung cancer patients using a reusable conducting polymer nanostructure.
Lee H; Jeon S; Seo JS; Goh SH; Han JY; Cho Y
Biomaterials; 2016 Sep; 101():251-7. PubMed ID: 27294542
[TBL] [Abstract][Full Text] [Related]
15. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
16. Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer.
Zhou J; Chang L; Guan Y; Yang L; Xia X; Cui L; Yi X; Lin G
PLoS One; 2016; 11(7):e0159708. PubMed ID: 27459628
[TBL] [Abstract][Full Text] [Related]
17. Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.
Denis JA; Patroni A; Guillerm E; Pépin D; Benali-Furet N; Wechsler J; Manceau G; Bernard M; Coulet F; Larsen AK; Karoui M; Lacorte JM
Mol Oncol; 2016 Oct; 10(8):1221-31. PubMed ID: 27311775
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.
Ignatiadis M; Rack B; Rothé F; Riethdorf S; Decraene C; Bonnefoi H; Dittrich C; Messina C; Beauvois M; Trapp E; Goulioti T; Tryfonidis K; Pantel K; Repollet M; Janni W; Piccart M; Sotiriou C; Litiere S; Pierga JY
Eur J Cancer; 2016 Aug; 63():97-104. PubMed ID: 27289552
[TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Holds Its Own in Tumor Profiling.
Cancer Discov; 2016 Jul; 6(7):686. PubMed ID: 27287288
[TBL] [Abstract][Full Text] [Related]
20. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Zhou Q; Li W; Leng B; Zheng W; He Z; Zuo M; Chen A
PLoS One; 2016; 11(6):e0155495. PubMed ID: 27253331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]